Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant - Seite 2

FDA scientific and program staff will actively collaborate with Northeastern University, The TIM Company, and Simulations Plus. Dr. Pepin, with assistance from Dr. Maxime Le Merdy at Simulations Plus, will oversee the modeling and simulation activities of the contract.

Funding for this collaboration is made possible by the Food and Drug Administration through grant award 1U01FD007959-01. Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

About Professor Jie Shen’s Laboratory at Northeastern University

Professor Jie Shen’s laboratory at Northeastern University is dedicated to innovative and collaborative interdisciplinary pharmaceutical and biomedical research to enhance public access to high quality and cost-effective medications to ultimately improve public health. Professor Shen’s laboratory is specialized in the formulation development and characterization, bioequivalence assessment strategies, and IVIVC (in vitro-in vivo correlation) of complex drug products (such as long-acting or locally-acting dosage forms, nanomedicines, modified release formulations). For more information, visit our website or follow us on LinkedIn. Founded in 1898, Northeastern is a global research university and the recognized leader in experience-driven lifelong learning. Our world-renowned experiential approach empowers our students, faculty, alumni, and partners to create impact far beyond the confines of discipline, degree, and campus.

About The TIM Company

The TIM Company expands its legacy of expertise within in vitro gastrointestinal models, combining over 35 years of experience. Headquartered in Delft, The Netherlands, The TIM Company is driven by the goal of developing alternative technologies to dissolution methods and animal research. Through its highly predictive technologies, it strongly contributes to the successful evaluation of oral formulation behavior and formulation performance prior to entering clinical trials. Data from TIM have guided clients worldwide with decision-making in different stages of oral drug development, i.e., led to the decrease in formulation reiterations, effectively de-risked clinical trials, and shortened time-to-market. For more information, visit our website at www.theTIMcompany.com or follow us on LinkedIn.